Basel Medical Group Putting On Hold On The Acquisition of BTC Digital Asset
Acquisition on Hold: Basel Medical Group Ltd has decided to pause its acquisition of Bitcoin (BTC) digital assets due to ongoing regulatory reviews by US authorities, seeking greater clarity before proceeding with the transaction.
Company Overview: Basel Medical Group is a Singapore-based provider specializing in orthopedic and trauma services, with over 20 years of experience and a strong business model supported by relationships in various industries.
Discover Tomorrow's Bullish Stocks Today
Analyst Views on BMGL
About BMGL
About the author
Basel Medical Group (BMGL) Receives Nasdaq Notice, Must Regain Compliance in 180 Days
- Nasdaq Warning: Basel Medical Group has received a notice from Nasdaq for failing to meet the $1 minimum bid price requirement after 30 consecutive trading days below this level, facing potential delisting risks and needing to take action within 180 days.
- Compliance Deadline: The company must maintain a closing bid price of at least $1 for 10 consecutive business days within 180 days, with a potential reverse stock split required before July 21, 2026, to meet Nasdaq's requirements.
- Response Plan: Basel Medical Group stated it is working with advisers to prepare a plan to address the listing non-compliance, aiming to implement effective measures to restore its stock price and ensure continued listing.
- Stock Price Reaction: Despite facing compliance challenges, Basel Medical Group's shares rose by 2.54%, indicating market confidence in the company's ability to regain compliance in the future.
Basel Medical Group Receives Delinquency Notice from Nasdaq
Delinquency Notification: Basel Medical Group Ltd. received a delinquency notification from Nasdaq due to an incomplete annual report for the fiscal year ending June 30, 2025, which lacked an auditor's opinion on its financial statements.
Compliance Timeline: The company has 60 days to submit a plan to regain compliance with Nasdaq rules, with a potential extension of up to 180 days if the plan is approved.
Financial Performance: For the fiscal year 2025, Basel Medical reported a net loss of S$12.09 million, a significant decline from a profit of S$2.07 million the previous year, despite an increase in sales from S$10.05 million to S$11.32 million.
Stock Performance: On the Nasdaq, BMGL shares closed at $1.14, reflecting a 2.52% decrease.
